<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826549</url>
  </required_header>
  <id_info>
    <org_study_id>COCO</org_study_id>
    <nct_id>NCT04826549</nct_id>
  </id_info>
  <brief_title>A Comparison of Exhaled Carbon Monoxide Measurements Using the iCOquit Smokerlyzer and Vitalograph Breath CO Monitor vs Carboxyhemoglobin From Venous Samples While Validating a Mobile Research Application</brief_title>
  <acronym>COCO</acronym>
  <official_title>A Comparison of Exhaled Carbon Monoxide Measurements Using the iCOquit Smokerlyzer and Vitalograph Breath CO Monitor vs Carboxyhemoglobin From Venous Samples While Validating a Mobile Research Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rose Research Center, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for a Smoke-Free World</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rose Research Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the accuracy and precision of the iCOquit&#xD;
      Smokerlyzer as compared with the gold standard of COHb levels measured in venous plasma&#xD;
      samples, as well as assessing its agreement with the Vitalograph BreathCO monitor. Validating&#xD;
      the precision and accuracy of the iCOquit Smokerlyzer could establish an additional, less&#xD;
      expensive, reliable method for determining smoking status in tobacco research. Additionally,&#xD;
      the portability of the device would allow for remote biochemical verification of smoking&#xD;
      status, thus enlarging the number of participants that can be included in intervention&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>eCO Monitor Accuracy compared to COHb</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine the accuracy and precision of the iCOquit Smokerlyzer as compared with the gold standard of COHb levels measured in venous plasma samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eCO Monitor's agreement with the Vitalograph BreathCO monitor</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparing the CO values from the eCO Monitor and the Vitalograph BreathCO monitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>eRESEARCH APP VALIDATION</measure>
    <time_frame>Daily for 5 days</time_frame>
    <description>Validate a new mobile app called eResearch through specific functionality testing by study participants.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Smoking, Cigarette</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Combustible cigarette smokers from Raleigh, NC and Charlotte, NC and surrounding areas.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has signed the ICF and is able to read and understand the information provided in the&#xD;
             ICF.&#xD;
&#xD;
          2. Is 21 to 65 years of age (inclusive) at screening.&#xD;
&#xD;
          3. No intention of quitting smoking in the next 30 days.&#xD;
&#xD;
          4. Willing and able to comply with the requirements of the study.&#xD;
&#xD;
          5. Owns a smartphone running iOS or Android with text message and data capabilities&#xD;
             compatible with the eResearch app.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is unhealthy or cannot participate in the study for any reason (e.g., medical,&#xD;
             psychiatric, and/or social reason) as judged by the Investigators or designated&#xD;
             medical staff based on all available assessments from the screening period (e.g.,&#xD;
             vital signs, physical examination, concomitant medications and medical history).&#xD;
&#xD;
          2. PHQ-9 score greater than 9, or a score greater than 0 on item #9 (&quot;Thoughts you would&#xD;
             be better off dead, or of hurting yourself in some way&quot;) at screening.&#xD;
&#xD;
          3. Body mass index (BMI) greater than 40.0 kg/m2&#xD;
&#xD;
          4. Use of any of these products in the past 30 days:&#xD;
&#xD;
               1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC,&#xD;
                  amphetamines, methamphetamines, or opiates),&#xD;
&#xD;
               2. Experimental (investigational) drugs that are unknown to participant,&#xD;
&#xD;
               3. Chronic opioid use.&#xD;
&#xD;
          5. Pregnant or nursing (by self-report) or positive urine pregnancy test.&#xD;
&#xD;
          6. Participant enrollment numbers met.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Mercedes</last_name>
      <phone>704-350-2999</phone>
      <email>derek.mercedes@roseresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Jed E Rose, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perry Willette, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy L Drew, MS, MHS, PA-C</last_name>
      <phone>919-325-2345</phone>
      <email>stacy.drew@roseresearchcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Tanaia Loeback</last_name>
      <email>tanaia.loeback@roseresearchcener.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jed E Rose, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perry Willette, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

